EP1576145A4 - GROUP DETECTABLE BY BIO-COMPUTING NEW VIRAL REGULATORY GENES AND USES THEREOF - Google Patents

GROUP DETECTABLE BY BIO-COMPUTING NEW VIRAL REGULATORY GENES AND USES THEREOF

Info

Publication number
EP1576145A4
EP1576145A4 EP03811859A EP03811859A EP1576145A4 EP 1576145 A4 EP1576145 A4 EP 1576145A4 EP 03811859 A EP03811859 A EP 03811859A EP 03811859 A EP03811859 A EP 03811859A EP 1576145 A4 EP1576145 A4 EP 1576145A4
Authority
EP
European Patent Office
Prior art keywords
genes
vgam
vgr
group
bio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03811859A
Other languages
German (de)
French (fr)
Other versions
EP1576145A2 (en
Inventor
Itzhak Bentwich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Genomics Ltd
Original Assignee
Rosetta Genomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/604,945 external-priority patent/US7696342B1/en
Priority claimed from US10/604,942 external-priority patent/US7696334B1/en
Priority claimed from US10/605,840 external-priority patent/US20070077553A1/en
Application filed by Rosetta Genomics Ltd filed Critical Rosetta Genomics Ltd
Publication of EP1576145A2 publication Critical patent/EP1576145A2/en
Publication of EP1576145A4 publication Critical patent/EP1576145A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/10—Production naturally occurring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a first group of novel genes, here identified as genomic address messenger or VGAM genes, and a second group of novel operon-like genes, here identified as viral genomic record or VGR genes. VGAM genes selectively inhibit translation of known `target' genes, many of which are known to be involved in various diseases. Nucleic acid molecules are provided respectively encoding 1560 VGAM genes, and 205 VGR genes, as are vectors and probes both comprising the nucleic acid molecules, and methods and systems for detecting VGAM and VGR genes and specific functions and utilities thereof, for detecting expression of VGAM and VGR genes, and for selectively enhancing and selectively inhibiting translation of the respective target genes thereof.
EP03811859A 2002-12-05 2003-11-26 GROUP DETECTABLE BY BIO-COMPUTING NEW VIRAL REGULATORY GENES AND USES THEREOF Withdrawn EP1576145A4 (en)

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
US604984 1984-04-27
US604944 2000-06-27
US604943 2000-06-27
US308778 2002-11-26
US31018802A 2002-12-05 2002-12-05
US310188 2002-12-05
US44124103P 2003-01-17 2003-01-17
US41123003P 2003-01-17 2003-01-17
US441241P 2003-01-17
US411230P 2003-01-17
US45778803P 2003-03-27 2003-03-27
US457788P 2003-03-27
US604945 2003-08-27
US10/604,945 US7696342B1 (en) 2002-11-26 2003-08-27 Bioinformatically detectable group of novel viral regulatory genes and uses thereof
US604942 2003-08-27
US10/604,942 US7696334B1 (en) 2002-12-05 2003-08-27 Bioinformatically detectable human herpesvirus 5 regulatory gene
US10/604,944 US7217807B2 (en) 2002-11-26 2003-08-28 Bioinformatically detectable group of novel HIV regulatory genes and uses thereof
US10/604,943 US7790867B2 (en) 2002-12-05 2003-08-28 Vaccinia virus-related nucleic acids and microRNA
US10/604,984 US7759478B1 (en) 2002-12-05 2003-08-29 Bioinformatically detectable viral regulatory genes
US10/605,838 US20080188428A1 (en) 2002-11-26 2003-10-30 Bioinformatically detectable group of novel hiv regulatory genes and uses thereof
US605840 2003-10-30
US10/605,840 US20070077553A1 (en) 2003-10-30 2003-10-30 Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US605838 2003-10-30
PCT/IL2003/000998 WO2004048511A2 (en) 2002-11-26 2003-11-26 Bioinformatically detectable group of novel viral regulatory genes and uses thereof

Publications (2)

Publication Number Publication Date
EP1576145A2 EP1576145A2 (en) 2005-09-21
EP1576145A4 true EP1576145A4 (en) 2007-06-13

Family

ID=39684558

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03811859A Withdrawn EP1576145A4 (en) 2002-12-05 2003-11-26 GROUP DETECTABLE BY BIO-COMPUTING NEW VIRAL REGULATORY GENES AND USES THEREOF

Country Status (4)

Country Link
US (6) US7217807B2 (en)
EP (1) EP1576145A4 (en)
AU (1) AU2003302409A1 (en)
WO (1) WO2004048511A2 (en)

Families Citing this family (201)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US9719094B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting SEC61G
US7612196B2 (en) 2002-11-14 2009-11-03 Dharmacon, Inc. siRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B)
US7592442B2 (en) 2002-11-14 2009-09-22 Dharmacon, Inc. siRNA targeting ribonucleotide reductase M2 polypeptide (RRM2 or RNR-R2)
US9879266B2 (en) 2002-11-14 2018-01-30 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7619081B2 (en) 2002-11-14 2009-11-17 Dharmacon, Inc. siRNA targeting coatomer protein complex, subunit beta 2 (COPB2)
US8090542B2 (en) 2002-11-14 2012-01-03 Dharmacon Inc. Functional and hyperfunctional siRNA
US7691998B2 (en) 2002-11-14 2010-04-06 Dharmacon, Inc. siRNA targeting nucleoporin 62kDa (Nup62)
US8198427B1 (en) 2002-11-14 2012-06-12 Dharmacon, Inc. SiRNA targeting catenin, beta-1 (CTNNB1)
US9228186B2 (en) 2002-11-14 2016-01-05 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7951935B2 (en) 2002-11-14 2011-05-31 Dharmacon, Inc. siRNA targeting v-myc myelocytomatosis viral oncogene homolog (MYC)
US9719092B2 (en) 2002-11-14 2017-08-01 Thermo Fisher Scientific Inc. RNAi targeting CNTD2
US9771586B2 (en) 2002-11-14 2017-09-26 Thermo Fisher Scientific Inc. RNAi targeting ZNF205
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US10011836B2 (en) 2002-11-14 2018-07-03 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
US7635770B2 (en) 2002-11-14 2009-12-22 Dharmacon, Inc. siRNA targeting protein kinase N-3 (PKN-3)
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
US9839649B2 (en) 2002-11-14 2017-12-12 Thermo Fisher Scientific Inc. Methods and compositions for selecting siRNA of improved functionality
AU2003298718A1 (en) * 2002-11-22 2004-06-18 University Of Massachusetts Modulation of hiv replication by rna interference
US8546082B2 (en) 2003-09-11 2013-10-01 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
US8288523B2 (en) 2003-09-11 2012-10-16 Ibis Biosciences, Inc. Compositions for use in identification of bacteria
US8097416B2 (en) 2003-09-11 2012-01-17 Ibis Biosciences, Inc. Methods for identification of sepsis-causing bacteria
JP5654722B2 (en) 2003-11-26 2015-01-14 ユニバーシティ オブ マサチューセッツ Sequence-specific inhibition of short RNA function
US20050182005A1 (en) * 2004-02-13 2005-08-18 Tuschl Thomas H. Anti-microRNA oligonucleotide molecules
WO2005079397A2 (en) * 2004-02-13 2005-09-01 Rockefeller University Anti-microrna oligonucleotide molecules
US7416842B2 (en) 2004-04-05 2008-08-26 The Rockefeller University DNA virus microRNA
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
EP1735459B1 (en) * 2004-04-07 2012-01-25 Exiqon A/S Methods for quantification of micrornas and small interfering rnas
US8192937B2 (en) 2004-04-07 2012-06-05 Exiqon A/S Methods for quantification of microRNAs and small interfering RNAs
US7365058B2 (en) 2004-04-13 2008-04-29 The Rockefeller University MicroRNA and methods for inhibiting same
US7605250B2 (en) 2004-05-12 2009-10-20 Dharmacon, Inc. siRNA targeting cAMP-specific phosphodiesterase 4D
ATE557090T1 (en) * 2004-05-20 2012-05-15 Aes Chemunex S A POLYNUCLEOTIDES FOR DETECTING ESCHERICHIA COLI O157:H7 AND ESCHERICHIA COLI O157:NM VEROTOXIN PRODUCERS
EP2402465B1 (en) 2004-07-13 2014-11-19 Gen-Probe Incorporated Method and kit for detection of Hepatitis A virus nucleic acid
WO2006135400A2 (en) 2004-08-24 2006-12-21 Isis Pharmaceuticals, Inc. Methods for rapid identification of recombinant organisms
CA2605701C (en) 2005-04-29 2015-12-08 Rockefeller University Human micrornas and methods for inhibiting same
US7718369B2 (en) 2005-09-12 2010-05-18 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9957569B2 (en) * 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US7662949B2 (en) * 2005-11-25 2010-02-16 Coley Pharmaceutical Gmbh Immunostimulatory oligoribonucleotides
US8014956B2 (en) 2005-12-30 2011-09-06 Industrial Technology Research Institute MicroRNA precursors
JP5425474B2 (en) * 2006-01-26 2014-02-26 アイシス ファーマシューティカルズ， インコーポレーテッド Composition and use thereof for huntingtin
US8163482B2 (en) 2006-02-23 2012-04-24 Nicholas Katsanis BBS10 related diagnostic methods for Bardet-Biedl syndrome
CN101466836A (en) 2006-04-11 2009-06-24 卫材R&D管理有限公司 Dopaminergic neuron progenitor cell marker 187A5
AU2007279205B2 (en) * 2006-07-28 2013-09-26 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
US8106004B2 (en) * 2006-07-28 2012-01-31 Children's Memorial Hospital Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
EP4082551A1 (en) 2006-08-08 2022-11-02 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
EP1897891A1 (en) * 2006-09-11 2008-03-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) Diagnosis of hereditary spastic paraplegias (HSP) by detection of a mutation in the KIAA1840 gene or protein
EP2074225B1 (en) 2006-10-10 2014-12-03 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Prostate cancer-specific alterations in erg gene expression and detection and treatment methods based on those alterations
JP2010508855A (en) * 2006-11-08 2010-03-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン SPINK1 and its use as a prostate cancer marker
US20080171719A1 (en) * 2006-11-28 2008-07-17 Alcon Manufacturing, Ltd. RNAi-MEDIATED INHIBITION OF AQUAPORIN 1 FOR TREATMENT OF IOP-RELATED CONDITIONS
JP2010515921A (en) * 2007-01-11 2010-05-13 ジェネンテック， インコーポレイテッド Genetic variation associated with tumors
WO2008089265A2 (en) * 2007-01-17 2008-07-24 University Of Georgia Research Foundation, Inc. Anti-viral methods and compositions
EA025296B1 (en) 2007-04-05 2016-12-30 Байер Кропсайенс Н.В. Insect resistant cotton plants and methods for identifying same
US8691965B2 (en) 2007-06-14 2014-04-08 Mirx Therapeutics Aps Oligonucleotides for modulating target RNA activity
WO2009009431A2 (en) 2007-07-06 2009-01-15 The Regents Of The University Of Michigan Mipol1-etv1 gene rearrangements
GB2453173A (en) 2007-09-28 2009-04-01 Dxs Ltd Polynucleotide primers
EP2203558B1 (en) 2007-10-18 2016-05-04 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
BRPI0820564A2 (en) 2007-11-13 2017-05-23 Phoenix Biotechnology Inc method for determining the likelihood of a therapeutic response in cardiac glycoside cancer chemotherapy
US20100323967A1 (en) * 2007-12-07 2010-12-23 Santaris Pharma A/S RNA Antagonist Compounds for the Modulation of MCL-1
DE102008013622A1 (en) * 2008-03-10 2009-09-17 Freie Universität Berlin Pharmaceutical composition for the diagnosis or treatment of the plasmocytoma
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
US8488863B2 (en) * 2008-11-06 2013-07-16 Los Alamos National Security, Llc Combinational pixel-by-pixel and object-level classifying, segmenting, and agglomerating in performing quantitative image analysis that distinguishes between healthy non-cancerous and cancerous cell nuclei and delineates nuclear, cytoplasm, and stromal material objects from stained biological tissue materials
CN102292457B (en) 2008-11-25 2014-04-09 简·探针公司 Compositions and methods for detecting small RNAS, and uses thereof
JP2012514475A (en) * 2009-01-09 2012-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Reproducible gene fusions in cancer
WO2010100437A2 (en) * 2009-03-05 2010-09-10 University Of Sheffield Production of protein
US20110038852A1 (en) * 2009-06-10 2011-02-17 3-V Biosciences, Inc. Antivirals that target transporters, carriers, and ion channels
US20120184447A1 (en) * 2009-06-26 2012-07-19 Reinhold Wasserkort Methods and Nucleic Acids for Analysis of Bladder Cell Proliferative Disorders
JP6189594B2 (en) 2009-08-11 2017-08-30 クルナ・インコーポレーテッド Treatment of adiponectin (ADIPOQ) -related diseases by suppression of natural antisense transcripts against adiponectin (ADIPOQ)
US8642271B2 (en) * 2009-08-27 2014-02-04 Case Western Reserve University Aberrant methylation of C6Orf150 DNA sequences in human colorectal cancer
JP5800817B2 (en) 2009-09-17 2015-10-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Recurrent gene fusion in prostate cancer
EP2309001A1 (en) * 2009-09-23 2011-04-13 SIRS-Lab GmbH Method for in vitro recording and differentiation of pathophysiological states
DE102009044085A1 (en) * 2009-09-23 2011-11-17 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
US20110076685A1 (en) * 2009-09-23 2011-03-31 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
ES2664591T3 (en) 2009-09-25 2018-04-20 Curna, Inc. Treatment of phylagrin-related diseases (flg) by modulating the expression and activity of the FLG gene
JP6031356B2 (en) * 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Treatment of uncoupling protein 2 (UCP2) -related diseases by inhibition of natural antisense transcripts against UCP2.
IL265674B2 (en) 2010-03-24 2024-05-01 Phio Pharm Corp Rna interference in dermal and fibrotic indications
US9095504B2 (en) 2010-03-24 2015-08-04 Rxi Pharmaceuticals Corporation RNA interference in ocular indications
WO2011130371A1 (en) 2010-04-13 2011-10-20 Life Technologies Corporation Compositions and methods for inhibition of nucleic acids function
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
EP2569054A4 (en) * 2010-05-11 2013-10-02 Hampton University Office Of General Counsel APPARATUS, METHOD AND SYSTEM FOR MEASURING INSTANT GAMMA RADIATION AND OTHER BEAM-INDUCED RADIATION DURING HADRON THERAPY TREATMENTS FOR DOSE AND RANGE CHECKING USING IONIZING RADIATION DETECTION
ES2640755T3 (en) 2010-10-06 2017-11-06 Curna, Inc. Treatment of diseases related to Sialidase 4 (neu4) by inhibition of the natural antisense transcript to the neu4 gene
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
DE102011009470A1 (en) * 2011-01-21 2012-08-09 Friedrich-Schiller-Universität Jena Biologically active nucleotide molecules for the targeted killing of cells, use thereof and application kit
US9157125B2 (en) 2011-02-02 2015-10-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services GRIN2A mutations and use thereof for the diagnosis of melanoma
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
US10941399B2 (en) * 2011-04-14 2021-03-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for gene-specific demethylation by DNA methyltransferase (DNMT)-RNA interaction
WO2012158945A2 (en) * 2011-05-19 2012-11-22 The Scripps Research Institute Compositions and methods for treating charcot-marie-tooth diseases and related neuronal diseases
CA2837554A1 (en) * 2011-06-03 2012-12-06 Genomic Vision Assessment of cancer risk based on rnu2 cnv and interplay between rnu2 cnv and brca1
JP6188686B2 (en) * 2011-06-09 2017-08-30 カッパーアールエヌエー，インコーポレイテッド Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
JP6090937B2 (en) 2011-07-27 2017-03-08 国立大学法人京都大学 Novel dopaminergic neural progenitor cell marker
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
PL2760463T3 (en) 2011-09-20 2019-05-31 Univ North Carolina Chapel Hill Regulation of sodium channels by plunc proteins
US20130156808A1 (en) * 2011-11-22 2013-06-20 Stipan Jonjic Vaccine comprising beta-herpesvirus
FR2983212A1 (en) 2011-11-28 2013-05-31 Lfb Biotechnologies ANTI-FH APTAMERS, PROCESS FOR OBTAINING THEM AND USES THEREOF
US20140323581A1 (en) * 2011-12-05 2014-10-30 The Trustees Of Columbia University In The City Of New York Transcriptome wiring analysis in parkinson's disease and uses thereof
CA2860676A1 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
CN104066842A (en) * 2012-01-25 2014-09-24 独立行政法人科学技术振兴机构 Oligonucleotide for HIV detection, HIV detection kit, and HIV detection method
JO3623B1 (en) 2012-05-18 2020-08-27 Amgen Inc St2 antigen binding proteins
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
US10443052B2 (en) 2012-10-15 2019-10-15 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
US9977708B1 (en) 2012-11-08 2018-05-22 23Andme, Inc. Error correction in ancestry classification
US9213947B1 (en) 2012-11-08 2015-12-15 23Andme, Inc. Scalable pipeline for local ancestry inference
GB201304810D0 (en) * 2013-03-15 2013-05-01 Isis Innovation Assay
CA2909721A1 (en) * 2013-04-19 2014-10-23 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lone star virus
US9305257B2 (en) * 2013-05-20 2016-04-05 International Business Machines Corporation Adaptive cataclysms in genetic algorithms
JP2016520615A (en) * 2013-05-31 2016-07-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Methods of using IL-1 antagonists for treating Alzheimer's disease
BR112015029785B1 (en) * 2013-05-31 2023-04-25 The United States Of America, As Represented By The Secretary Department Of Health And Human Services METHOD TO SPECIFICALLY DETECT THE PRESENCE OR ABSENCE OF THE K70E MUTATION IN HIV-1 REVERSE TRANSCRIPTASE AND MIXTURE OF OLIGONUCLEOTIDES FOR THE SELECTIVE DETECTION OF THE 70E MUTATION IN HIV-1 REVERSE TRANSCRIPTASE
MX2016004651A (en) 2013-10-11 2016-08-05 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression.
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US9903940B2 (en) * 2013-12-30 2018-02-27 Qualcomm Incorporated Entrusted device localization scheme using ultrasound signatures
US9901478B2 (en) 2014-03-11 2018-02-27 Chine, Llc Methods and apparatuses for the external distraction in the assistance of spinal deformities
US10394828B1 (en) * 2014-04-25 2019-08-27 Emory University Methods, systems and computer readable storage media for generating quantifiable genomic information and results
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2016043666A1 (en) * 2014-09-19 2016-03-24 Agency For Science, Technology And Research Differentiation of hepatocyte-like cells from stem cells
AU2015327836B2 (en) 2014-10-03 2021-07-01 Cold Spring Harbor Laboratory Targeted augmentation of nuclear gene output
US9654308B2 (en) * 2014-11-19 2017-05-16 Intel Corporation Systems and methods for carrier frequency offset estimation for long training fields
US10616219B2 (en) * 2014-12-11 2020-04-07 FlowJo, LLC Single cell data management and analysis systems and methods
JP2018510621A (en) 2015-02-13 2018-04-19 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Patatin-like phospholipase domain-containing 3 (PNPLA3) iRNA compositions and methods of use thereof
NZ735777A (en) 2015-03-26 2023-03-31 Jacqueline M Iversen Methods and compositions to inhibit symptoms associated with veisalgia
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
DK3277815T3 (en) * 2015-04-03 2021-12-13 Univ Massachusetts OLIGONUCLEOTIDE COMPOUNDS FOR THE TREATMENT OF PRE-CLAMPSY AND OTHER ANGIOGENIC DISORDERS
WO2016161429A1 (en) 2015-04-03 2016-10-06 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating tmprss6 expression
EP3722424A1 (en) 2015-04-16 2020-10-14 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US10185803B2 (en) 2015-06-15 2019-01-22 Deep Genomics Incorporated Systems and methods for classifying, prioritizing and interpreting genetic variants and therapies using a deep neural network
EP3334499A4 (en) 2015-08-14 2019-04-17 University of Massachusetts BIOACTIVE CONJUGATES FOR THE ADMINISTRATION OF OLIGONUCLEOTIDES
WO2017048620A1 (en) * 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
CN108603230A (en) * 2015-10-09 2018-09-28 南安普敦大学 The screening of the adjusting of gene expression and protein expression imbalance
JP2018531046A (en) * 2015-10-14 2018-10-25 アクイナ ファーマシューティカルズ， インコーポレイテッド Nucleic acid based TIA-1 inhibitors
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
EP3390636B1 (en) 2015-12-14 2021-05-19 Cold Spring Harbor Laboratory Antisense oligomers for treatment of dravet syndrome
JOP20200228A1 (en) 2015-12-21 2017-06-16 Novartis Ag Compositions and methods for decreasing tau expression
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
CA3014773C (en) 2016-03-07 2025-11-18 Father Flanagan's Boys' Home Doing Business As Boys Town National Research Hospital Noninvasive molecular controls
TWI794171B (en) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-l1 inhibitors
TWI808055B (en) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Combination therapies of hdac inhibitors and pd-1 inhibitors
GB201609597D0 (en) 2016-06-01 2016-07-13 Univ Sheffield Therapy
CN114807152A (en) 2016-06-08 2022-07-29 哈佛学院院长及董事 Engineered viral vectors reduce induction of inflammation and immune responses
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
US12300357B2 (en) 2016-12-14 2025-05-13 FlowJo, LLC Applied computer technology for management, synthesis, visualization, and exploration of parameters in large multi-parameter data sets
AU2018264636B2 (en) * 2017-05-08 2022-03-17 Toolgen Incorporated Artificially manipulated immune cell
US11573182B2 (en) 2017-05-25 2023-02-07 FlowJo, LLC Visualization, comparative analysis, and automated difference detection for large multi-parameter data sets
CN110799647A (en) 2017-06-23 2020-02-14 马萨诸塞大学 Two-tailed self-delivery SIRNA and related methods
WO2019005822A1 (en) * 2017-06-28 2019-01-03 The Cleveland Clinic Foundation Treatment of nervous system injury and neurodegenerative disorders and related conditions
US10416226B2 (en) * 2017-08-03 2019-09-17 Globalfoundries Inc. Test response compaction scheme
EP3673080B1 (en) 2017-08-25 2023-10-18 Stoke Therapeutics, Inc. Antisense oligomers for treatment of conditions and diseases
EP3676393A4 (en) 2017-09-01 2021-10-13 Venn Biosciences Corporation IDENTIFICATION AND USE OF GLYCOPEPTIDES AS BIOMARKERS FOR DIAGNOSIS AND MONITORING OF TREATMENT
US20190102841A1 (en) * 2017-10-04 2019-04-04 Servicenow, Inc. Mapping engine configurations with task managed workflows and grid user interfaces
EP3707262A1 (en) 2017-11-08 2020-09-16 President and Fellows of Harvard College Compositions and methods for inhibiting viral vector-induced inflammatory responses
KR20200090869A (en) * 2017-11-30 2020-07-29 가부시키가이샤 리보믹 Anti-chimeric agent aptamers and uses thereof
TWI840345B (en) 2018-03-02 2024-05-01 美商Ionis製藥公司 Modulators of irf4 expression
AU2019239971B2 (en) * 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
JP2021523227A (en) 2018-05-04 2021-09-02 ストーク セラピューティクス，インク． Methods and Compositions for the Treatment of Cholesteryl Ester Accumulation
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
AU2019316640B2 (en) 2018-08-10 2026-03-12 University Of Massachusetts Modified oligonucleotides targeting SNPs
EP3840759A4 (en) 2018-08-23 2022-06-01 University Of Massachusetts FULLY STABILIZED O-METHYL RICH OLIGONUCLEOTIDES
CN109097465B (en) * 2018-09-19 2021-06-08 蒲佐 Application of SNP (single nucleotide polymorphism) site of CLIP3 gene
CN109355408B (en) * 2018-09-26 2021-09-21 华南理工大学 Primer, kit and method for PSR (phosphosilicate receptor) detection of Escherichia coli type I Shiga toxin
AU2019350786A1 (en) 2018-09-26 2021-05-13 Greenlight Biosciences, Inc. Control of Coleopteran insects
CN113227382A (en) 2018-11-08 2021-08-06 绿光生物科技股份有限公司 Control of insect infestation
SG11202105276TA (en) 2018-12-03 2021-06-29 Univ Texas Oligo-benzamide analogs and their use in cancer treatment
CN111363783B (en) * 2018-12-26 2024-01-02 武汉康测科技有限公司 T cell receptor library high-throughput sequencing library construction and sequencing data analysis method based on specific recognition sequence
US11581060B2 (en) * 2019-01-04 2023-02-14 President And Fellows Of Harvard College Protein structures from amino-acid sequences using neural networks
AU2020207935A1 (en) 2019-01-18 2021-08-26 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
CN109884007B (en) * 2019-02-18 2020-10-27 西安交通大学 Integrated synchronous DNA nano device and living cell multi-target imaging application and imaging method thereof
CN113748209A (en) 2019-02-27 2021-12-03 斯托克制药公司 Antisense oligomers for the treatment of conditions and diseases
CN110327498B (en) * 2019-04-15 2021-02-02 北京大学口腔医学院 Active small molecule controlled release method based on liposome and application thereof
US20210020266A1 (en) 2019-07-19 2021-01-21 23Andme, Inc. Phase-aware determination of identity-by-descent dna segments
CN110592044B (en) * 2019-07-26 2021-06-22 中国农业科学院蔬菜花卉研究所 Gene encoding protein kinase Fused and its application in the control of diamondback moth
KR20220047989A (en) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Chemically modified oligonucleotides targeting SNPs
EP4013297A4 (en) 2019-08-16 2023-12-13 Poltorak Technologies, LLC DEVICE AND METHOD FOR MEDICAL DIAGNOSIS
CN114341355A (en) * 2019-08-27 2022-04-12 国立大学法人东海国立大学机构 Gastric cancer molecule targeted nucleic acid medicine
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
CN110596403B (en) * 2019-09-17 2022-12-16 中山大学附属第一医院 Specific protein marker and preparation method for ovarian cancer diagnosis
CN110572216A (en) * 2019-09-17 2019-12-13 成都芯瑞科技股份有限公司 optical module APC control software implementation method
KR20220080101A (en) * 2019-10-15 2022-06-14 트러스티스 오브 보스톤 칼리지 Chimeric thermostable aminoacyl-tRNA synthetase for improved unnatural amino acid incorporation
MX2022007144A (en) 2019-12-16 2022-07-11 Alnylam Pharmaceuticals Inc Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof.
CN111024850B (en) * 2019-12-25 2022-06-14 贵州大学 Preparation and application of a paraquat molecularly imprinted solid-phase microextraction coating solution
KR20220148188A (en) * 2020-03-03 2022-11-04 앱티튜드 메디칼 시스템즈, 아이엔씨. Aptamers and uses thereof
WO2021216114A1 (en) 2020-04-22 2021-10-28 Houston Gene Therapeutics Llc Compositions for treatment of vascular disease
AU2021270720A1 (en) 2020-05-11 2022-12-08 Stoke Therapeutics, Inc. OPA1 antisense oligomers for treatment of conditions and diseases
US12534724B2 (en) 2020-05-26 2026-01-27 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
US11817176B2 (en) 2020-08-13 2023-11-14 23Andme, Inc. Ancestry composition determination
TW202227627A (en) 2020-09-11 2022-07-16 美商愛羅海德製藥公司 Rnai agents for inhibiting expression of dux4, compositions thereof, and methods of use
EP4226289A1 (en) * 2020-10-12 2023-08-16 Telefonaktiebolaget LM Ericsson (publ) Data pruning tool and related aspects
CN112400904B (en) * 2020-11-19 2021-06-25 山东农业大学 Application of miR-995 in the control of lepidopteran pests
CN112553054A (en) * 2020-12-10 2021-03-26 上海艾众生物科技有限公司 Cell separation apparatus for bioreactor
EP4304353A4 (en) 2021-03-08 2025-02-12 Greenlight Biosciences, Inc. RNA-BASED CONTROL OF VINE POWDERY MILDEW
CN113106154B (en) * 2021-04-16 2022-10-25 上海市第一妇婴保健院 Application of PRMT3 in diagnosis or treatment of recurrent spontaneous abortion
GB202107586D0 (en) * 2021-05-27 2021-07-14 Complement Therapeutics Ltd Inhibitory nucleic acids for Factor H family proteins
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
CN113234737A (en) * 2021-06-30 2021-08-10 安徽农业大学 Application of MYB transcription factor gene of tea tree in regulating and controlling caffeine biosynthesis of tea tree
MX2024007790A (en) 2021-12-22 2024-09-06 Camp4 Therapeutics Corp MODULATION OF GENE TRANSCRIPTION USING ANTISENSE OLIGONUCLEOTIDES TARGETING REGULATORY RNAS.
WO2023133072A2 (en) * 2022-01-07 2023-07-13 Jumio Corporation Biometric authentication using head-mounted devices
CN114836580B (en) * 2022-06-02 2024-05-10 昆明理工大学 Multiplex qPCR detection primer combination for respiratory tract infectious disease pathogens
EP4577674A1 (en) * 2022-08-24 2025-07-02 F. Hoffmann-La Roche AG Compositions and methods for detecting monkeypox virus
AU2023348346A1 (en) * 2022-09-30 2025-03-27 Contera Pharma A/S Antisense oligonucleotides for the treatment of canavan disease
WO2024259175A2 (en) * 2023-06-13 2024-12-19 Nephrogen Inc. Systems, methods, and compositions for de-repressing pkd1
WO2025163033A1 (en) * 2024-01-30 2025-08-07 Universiteit Maastricht Compounds for use in the treatment of disorders or diseases through modulation of transcription factor gata4 activity
WO2025213093A1 (en) * 2024-04-04 2025-10-09 Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center Antisense oligonucleotides for treating pitt hopkin syndrome
CN120775793B (en) * 2025-09-04 2025-11-11 海南热带海洋学院崖州湾创新研究院 Application of the Six2 gene in promoting the reprogramming of fibroblasts into muscle stem cells

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743364A2 (en) * 1995-05-18 1996-11-20 Commissariat A L'energie Atomique Nucleic acid fragments derived form the HIV-1 genome, corresponding fragments and their application as reactives for risk evaluation of HIV-1 mother-foetal transmission
EP1203826A2 (en) * 2000-10-30 2002-05-08 Tosoh Corporation Oligonucleotide for detection of HIV-1 and detection method

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US6027880A (en) * 1995-08-02 2000-02-22 Affymetrix, Inc. Arrays of nucleic acid probes and methods of using the same for detecting cystic fibrosis
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
NO972006D0 (en) 1997-04-30 1997-04-30 Forskningsparken I Aas As New method for diagnosis of diseases
US6849431B2 (en) * 1997-07-25 2005-02-01 Ryoji Tamura Non-B, non-C, non-G hepatitis virus gene, polynucleotide, polypeptide, virus particle, method for isolating virus particle, and method for detecting virus
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
WO1999034016A2 (en) * 1997-12-29 1999-07-08 Genena Ltd. A method for identifying and characterizing cells and tissues
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6107091A (en) * 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
EP1013775A1 (en) * 1998-12-21 2000-06-28 LUTZ, Hans Quantitative polymerase chain reaction using a fluorogenic real-time detection system
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
US6136603A (en) * 1999-03-26 2000-10-24 Isis Pharmaceuticals Inc. Antisense modulation of interleukin-5 signal transduction
DE60025391D1 (en) * 1999-10-26 2006-03-30 Immusol Inc RIBOZYM THERAPY FOR THE TREATMENT OF PROLIFERATIVE EYE SKINS
GB9925459D0 (en) 1999-10-27 1999-12-29 Plant Bioscience Ltd Gene silencing
US6903247B2 (en) * 2000-02-08 2005-06-07 Cornell Research Foundation, Inc. Constitutive α-Tubulin promoter from coffee plants and uses thereof
WO2003070918A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
EP1272630A2 (en) 2000-03-16 2003-01-08 Genetica, Inc. Methods and compositions for rna interference
PT1309726E (en) 2000-03-30 2010-03-08 Whitehead Biomedical Inst RNA INTERFERENCE-SPECIFIC RNA INTERFERENCE MEDIATORS
US6503756B1 (en) * 2000-09-22 2003-01-07 Isis Pharmaceuticals, Inc. Antisense modulation of syntaxin 4 interacting protein expression
US6692954B1 (en) * 2000-11-03 2004-02-17 The Scripps Research Institute Generation of human cytomegalovirus yeast artificial chromosome recombinants
KR100909681B1 (en) 2000-12-01 2009-07-29 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. Small RNA molecules that mediate JR interference
US6566132B1 (en) * 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
AU2002316135B9 (en) 2001-05-18 2009-05-28 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20030175950A1 (en) * 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
SE519066C2 (en) 2001-05-21 2003-01-07 Sca Hygiene Prod Ab Absorbent articles provided with a belt comprising stiffening elements
JP4371812B2 (en) 2001-09-28 2009-11-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ MicroRNA molecules
AU2003216255A1 (en) 2002-02-20 2003-09-09 Ribozyme Pharmaceuticals, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MDR P-GLYCOPROTEIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
WO2003093441A2 (en) 2002-05-03 2003-11-13 Duke University A method of regulating gene expression
US20030228691A1 (en) 2002-05-17 2003-12-11 Lewis David L. Processes for inhibiting gene expression using polynucleotides
US20040106566A1 (en) 2002-05-17 2004-06-03 Shi-Lung Lin RNA-splicing and processing-directed gene silencing and the relative applications thereof
US6989442B2 (en) 2002-07-12 2006-01-24 Sirna Therapeutics, Inc. Deprotection and purification of oligonucleotides and their derivatives
CA2492917C (en) 2002-07-19 2011-10-18 University Of South Carolina Compositions and methods for the modulation of gene expression in plants
WO2004015063A2 (en) 2002-08-07 2004-02-19 Tularik Inc. Amplification and overexpression of oncogenes
JP4679149B2 (en) 2002-09-30 2011-04-27 オンコセラピー・サイエンス株式会社 Genes and polypeptides related to human pancreatic cancer
US7314750B2 (en) * 2002-11-20 2008-01-01 Affymetrix, Inc. Addressable oligonucleotide array of the rat genome
WO2005001128A2 (en) * 2003-04-11 2005-01-06 University Of Florida Research Foundation, Inc. Materials and methods for producing dna libraries and detecting and identifying microorganisms
AU2004263824A1 (en) * 2003-06-05 2005-02-17 Wyeth Nucleic acid arrays for detecting multiple strains of a non-viral species
US8088902B2 (en) * 2004-04-05 2012-01-03 The Rockefeller University DNA virus microRNA and methods for inhibiting same
WO2006113431A2 (en) * 2005-04-13 2006-10-26 University Of Massachusetts Dual functional oligonucleotides for use as anti-viral agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743364A2 (en) * 1995-05-18 1996-11-20 Commissariat A L'energie Atomique Nucleic acid fragments derived form the HIV-1 genome, corresponding fragments and their application as reactives for risk evaluation of HIV-1 mother-foetal transmission
EP1203826A2 (en) * 2000-10-30 2002-05-08 Tosoh Corporation Oligonucleotide for detection of HIV-1 and detection method

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CAPODICI J: "Inhibition of HIV-1 infection by small interfering RNA-mediated RNA interference", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 169, October 2002 (2002-10-01), pages 5196 - 5201, XP002988100, ISSN: 0022-1767 *
DATABASE EMBL [online] 14 October 1996 (1996-10-14), "Sequence 3 from patent US 5512438.", retrieved from EBI accession no. EMBL:I19741 Database accession no. I19741 *
DATABASE GENESEQ [online] 23 April 1999 (1999-04-23), "HIV-1 TAR mimetic oligonucleotide 1346.", retrieved from EBI accession no. GSN:AAX05666 Database accession no. AAX05666 *
DATABASE GENESEQ [online] 25 March 1999 (1999-03-25), "HIV-1 RNA TAR sequence.", retrieved from EBI accession no. GSN:AAV81502 Database accession no. AAV81502 *
DATABASE GENESEQ [online] 9 September 1999 (1999-09-09), "HIV TAR derived RNA fragment.", retrieved from EBI accession no. GSN:AAX88048 Database accession no. AAX88048 *
GOTTWEIN E. ET AL: "viral and cellular MicroRNAs as dterminants of viral pathogenesis and immunity", CELL HOST & MICROBE, ELSEVIER, NL LNKD- DOI:10.1016/J.CHOM.2008.05.002, vol. 3, 12 June 2008 (2008-06-12), pages 375 - 387, XP002509429, ISSN: 1931-3128 *
NOVINA C D ET AL: "siRNA directed inhibition of HIV-1 infection", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 7, no. 8, July 2002 (2002-07-01), pages 681 - 686, XP002955298, ISSN: 1078-8956 *
PARK W S ET AL: "Specific inhibition of HIV-1 gene expression by double-stranded RNA.", NUCLEIC ACIDS RESEARCH. SUPPLEMENT (2001) 2001, no. 1, 2001, pages 219 - 220 *
PARK WEE-SUNG ET AL: "Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference.", NUCLEIC ACIDS RESEARCH 15 NOV 2002, vol. 30, no. 22, 15 November 2002 (2002-11-15), pages 4830 - 4835, XP002430602, ISSN: 1362-4962 *

Also Published As

Publication number Publication date
EP1576145A2 (en) 2005-09-21
US20070031823A1 (en) 2007-02-08
US7217807B2 (en) 2007-05-15
US7790867B2 (en) 2010-09-07
US8207316B1 (en) 2012-06-26
US7777022B2 (en) 2010-08-17
WO2004048511A2 (en) 2004-06-10
US7759478B1 (en) 2010-07-20
WO2004048511A3 (en) 2005-12-15
AU2003302409A1 (en) 2004-06-18
US20040219515A1 (en) 2004-11-04
US20070042381A1 (en) 2007-02-22
US20080188428A1 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
EP1576145A4 (en) GROUP DETECTABLE BY BIO-COMPUTING NEW VIRAL REGULATORY GENES AND USES THEREOF
EP1185546A4 (en) HIGHLY SPECIFIC PRIMERS, AMPLIFICATION TECHNIQUES AND KITS
WO2006126040A8 (en) Bacterial and bacterial associated mirnas and uses thereof
WO2009135093A3 (en) Rnase-h-based assays utilizing modified rna monomers
WO2002038806A3 (en) Detection of nucleic acid polymorphisms
WO2004058990A3 (en) Genetic polymorphisms associated with stenosis, methods of detection and uses thereof
ATE538127T1 (en) 6-DISUBSTITUTED BICYCLIC NUCLEIC ACID ANALOGUES
WO2002020565A3 (en) Collections of repeat proteins comprising repeat modules
ATE409238T1 (en) DETECTION OF HYBRIDIZATION OF NUCLEIC ACIDS BY FLUORESCENCE POLARIZATION
WO2008009437A3 (en) Sdf-i binding nucleic acids
DK1948822T3 (en) Multicomponent nucleic acid enzymes and methods for their use
CY1111278T1 (en) security system
WO2007147159A3 (en) Functional nucleic acid ligands to fluorescent proteins
WO2007087310A3 (en) Nucleic acid analysis using sequence tokens
WO2008008553A3 (en) Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
ATE324465T1 (en) DETECTION METHOD USING INCREASED SILVER TINTING
WO2008009477A3 (en) Means for inhibiting the expression of protein kinase 3
WO2007142763A3 (en) Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
WO2005083127A3 (en) Genetic polymorphisms associated with stroke, methods of detection and uses thereof
WO2007050705A3 (en) Genetic polymorphisms associated with alzheimer's disease, methods of detection and uses thereof
WO2008118415A3 (en) Genetic polymorphisms associated with coronary events and drug response
BR0311768A (en) Identification of oligonucleotides for the capture, detection and quantification of hepatitis A virus nucleic acid
WO2005097205A8 (en) Dna virus microrna and methods for inhibiting same
WO2009061799A3 (en) Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
EP1480992A4 (en) INTERFERENCE BY TELOMERASE

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050616

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/48 20060101AFI20051222BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070511

17Q First examination report despatched

Effective date: 20080118

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110121